The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Recent progress in the diagnosis and treatment of ovarian cancer
Open accessAbstract
Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and the cancer antigen (CA) 125 tumor marker are currently under study and may lower stage at diagnosis but have not yet been shown to improve survival. Women who have inherited a deleterious mutation in the BRCA1 or BRCA2 gene and those with the Lynch syndrome (hereditary nonpolyposis colorectal cancer) have the highest risk of developing ovarian cancer but account for only approximately 10% of those with the disease. Other less common and less well-defined genetic syndromes may increase the risk of ovarian cancer, but their contribution to genetic risk is small. A clear etiology for sporadic ovarian cancer has not been identified, but risk is affected by reproductive and hormonal factors. Surgery has a unique role in ovarian cancer, as it is used not only for diagnosis and staging but also therapeutically, even in patients with widely disseminated, advanced disease. Ovarian cancer is highly sensitive to chemotherapy drugs, particularly the platinum agents, and most patients will attain a remission with initial treatment. Recent advances in the delivery of chemotherapy using the intraperitoneal route have further improved survival after initial therapy. Although the majority of ovarian cancer patients will respond to initial chemotherapy, most will ultimately develop disease recurrence. Chemotherapy for recurrent disease includes platinum-based, multiagent regimens for women whose disease recurs more than 6 to 12 months after the completion of initial therapy and sequential single agents for those whose disease recurs earlier. New targeted biologic agents, particularly those involved with the vascular endothelial growth factor pathway and those targeting the poly (ADP-ribose) polymerase (PARP) enzyme, hold great promise for improving the outcome of ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Self-citationNeoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Self-citationA Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Cited by
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram‐Baptiste, D., Saslow, D., Brawley, O. W., & Wender, R. C. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21392 · Cited by 719
CA125 and Ovarian Cancer: A Comprehensive Review
Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2020) · Cancers · doi:10.3390/cancers12123730 · Cited by 602
Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
Peres, L. C., Cushing-Haugen, K. L., Köbel, M., Harris, H. R., Berchuck, A., Rossing, M. A., Schildkraut, J. M., & Doherty, J. A. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy071 · Cited by 554
Smith, R. A., Manassaram-Baptiste, D., Brooks, D., Cokkinides, V., Doroshenk, M., Saslow, D., Wender, R. C., & Brawley, O. W. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21212 · Cited by 478
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022: Featured Updates to the NCCN Guidelines
Armstrong, D. K., Alvarez, R. D., Backes, F. J., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Chitiyo, V. C., Cristea, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0047 · Cited by 401
Self-citationEpigenetic therapy for ovarian cancer: promise and progress
Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 319
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
Self-citationCharacterization and proteomic analysis of ovarian cancer-derived exosomes
Liang, B., Peng, P., Chen, S., Li, L., Zhang, M., Cao, D., Yang, J., Li, H., Gui, T., Li, X., et al. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2012.12.029 · Cited by 308
The long story of camptothecin: From traditional medicine to drugs
Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., Sala, A., & Collina, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.085 · Cited by 296
Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models
Maenhoudt, N., Defraye, C., Boretto, M., Jan, Z., Heremans, R., Boeckx, B., Hermans, F., Arijs, I., Cox, B., Van Nieuwenhuysen, E., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.03.004 · Cited by 186
Gao, Y., Zeng, S., Xu, X., Li, H., Yao, S., Song, K., Li, X., Chen, L., Tang, J., Xing, H., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00278-8 · Cited by 185
Obesity and ovarian cancer risk: A systematic review
Foong, K. W., & Bolton, H. (2017) · Post Reproductive Health · doi:10.1177/2053369117709225 · Cited by 85
Specific cell targeting with APRPG conjugated PEG–PLGA nanoparticles for treating ovarian cancer
Wang, Y., Liu, P., Duan, Y., Yin, X., Wang, Q., Liu, X., Wang, X., Zhou, J., Wang, W., Qiu, L., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.062 · Cited by 56
SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis
YANG, M., XIE, X., & DING, Y. (2016) · Oncology Reports · doi:10.3892/or.2016.4545 · Cited by 30
Qiao, L., Chen, X., Xi, X., Chen, X., Zhang, P., Dong, H., Wu, X., & Chen, X. (2020) · Medicine · doi:10.1097/md.0000000000023329 · Cited by 22
Metadata
- Authors
- Jelovac, D., & Armstrong, D. K.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2011-04-27
- Volume
- 61
- Issue
- 3
- Pages
- 183-203
- ISSN
- 0007-9235 (ISSN-L)
- OpenAlex
- W1966932597
- Cited by
- 765
- References
- 103
- FWCI
- 35.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.